Table S1. Study search strategy. Table S2. Information on excluded studies. Table S3. List of Ongoing studies. Table S4. GRADE. Figure S1. Risk of bias summary. Figure S2. Risk of bias graph. Figure S3. Forest plot for vasopressin or its analogues on cardiovascular events. Figure S4. Forest plot for vasopressin or its analogues on arrhythmia. Figure S5. Forest plot for vasopressin or its analogues on mesenteric ischemia events. Figure S6. Forest plot for vasopressin or its analogues on diarrhea. Figure S7. Forest plot for vasopressin or its analogues on cerebrovascular events. Figure S8. Forest plot for vasopressin or its analogues on hyponatremia. Figure S7. Funnel plot for publication bias. (DOCX 554 kb
Assessment of bias. Table S2. Baseline characteristics for individual study groups. Table S3. Compar...
S1. Study population. S2. Determination of cumulative fluid balance. S3. Vasopressor standardization...
Figure S1. Flow diagram of study selection; Table S1. Primary and secondary endpoints, inclusion and...
Table S1. Rationale for Mahalanobis distance variable selection in the propensity matching of vasopr...
Table S1. Study characteristics: management description of included randomized controlled trials. Ta...
Figure S2. Funnel plots. Funnel plots were generally asymmetrical. The hollow dots and dotted line i...
Supplementary Methods. Figure S1. Flow chart showing the process of study selection and numbers of s...
Mean difference for vasoactive score. The forest plot demonstrates point estimates of mean differenc...
Figure S1. Assessment of risk of bias in included trials. Figure S2. Forrest plot based on aggregate...
Table S2. Summary of outcomes for the effect of Terlipressin in septic shock patients. (DOCX 21 kb
Forest plot showing the effects of early goal-direced therapy on vasopressor use rate. (TIF 968 kb
Mean difference for mean arterial pressure. The forest plot demonstrates point estimates of mean dif...
Figure S1. Kernel density plots of the propensity score before and after propensity score matching. ...
Network meta-analysis estimates and common standard deviation heterogeneity of primary and secondary...
Figure S1. Missing rate for clinical and laboratory variables extracted from the database. Variables...
Assessment of bias. Table S2. Baseline characteristics for individual study groups. Table S3. Compar...
S1. Study population. S2. Determination of cumulative fluid balance. S3. Vasopressor standardization...
Figure S1. Flow diagram of study selection; Table S1. Primary and secondary endpoints, inclusion and...
Table S1. Rationale for Mahalanobis distance variable selection in the propensity matching of vasopr...
Table S1. Study characteristics: management description of included randomized controlled trials. Ta...
Figure S2. Funnel plots. Funnel plots were generally asymmetrical. The hollow dots and dotted line i...
Supplementary Methods. Figure S1. Flow chart showing the process of study selection and numbers of s...
Mean difference for vasoactive score. The forest plot demonstrates point estimates of mean differenc...
Figure S1. Assessment of risk of bias in included trials. Figure S2. Forrest plot based on aggregate...
Table S2. Summary of outcomes for the effect of Terlipressin in septic shock patients. (DOCX 21 kb
Forest plot showing the effects of early goal-direced therapy on vasopressor use rate. (TIF 968 kb
Mean difference for mean arterial pressure. The forest plot demonstrates point estimates of mean dif...
Figure S1. Kernel density plots of the propensity score before and after propensity score matching. ...
Network meta-analysis estimates and common standard deviation heterogeneity of primary and secondary...
Figure S1. Missing rate for clinical and laboratory variables extracted from the database. Variables...
Assessment of bias. Table S2. Baseline characteristics for individual study groups. Table S3. Compar...
S1. Study population. S2. Determination of cumulative fluid balance. S3. Vasopressor standardization...
Figure S1. Flow diagram of study selection; Table S1. Primary and secondary endpoints, inclusion and...